Duke spin-out Regado Biosciences receives $43m in initial public offering.

Regardo Biosciences has raised $43m in its initial public offering (IPO) through the offering of 10.8 million shares at $4 a share, a revision down from its originally planned $5. The Duke University biotech spin-out, which is commercialising medical research that is designed to stop blood clotting, will be traded on the Nasdaq under the…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.